NCT01407198View on ClinicalTrials.gov

Nilotinib With Radiation for High Risk Chordoma

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

February 29, 2016

Study Completion Date

June 30, 2025

Conditions
Chordoma
Interventions
DRUG

Nilotinib

Orally, daily 200 - 400 mg BID

RADIATION

Radiation therapy

External beam radiation will be delivered at 1.8 Gy per day, 5 days per week (excluding holidays)for a total of 28 fractions over a 6 weeks period.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01407198 - Nilotinib With Radiation for High Risk Chordoma | Biotech Hunter | Biotech Hunter